ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

被引：0

作者：

Park, W. ^{[1
]}

Kwon, D. ^{[2
]}

Desai, A. ^{[1
]}

Florou, V. ^{[1
]}

Saravia, D. ^{[3
]}

Warsch, J. ^{[4
]}

Chae, Y. K. ^{[5
]}

Ishkanian, A. ^{[6
]}

Jahanzeb, M. ^{[7
]}

Mudad, R. ^{[8
]}

Lopes, G. ^{[9
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA

[3] Univ Miami, Miller Sch Med, Internal Med, Miami, FL 33136 USA

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA

[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA

[7] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Univ Miami, Sylvester Comprehens Canc Ctr, Global Oncol, Miami, FL USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

Predictive; PD-1; inhibitor; Clinical outcome;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.07-024

引用

页码：S2004 / S2004

页数：1

共 50 条

[21] Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer
Wang, Ziheng
Zhang, Bo
Zhang, Chenlin
Ren, Shiqi
Wang, Wei
Wang, Yingjing
Jiang, Tao
Wei, Hualin
Li, Yang
Wu, Qiong
Chen, Jianfeng
INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 74
[22] Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies
Sakakida, Tomoki
Ishikawa, Takeshi
Uchino, Junji
Tabuchi, Yusuke
Komori, Satoshi
Asai, Jun
Arai, Akihito
Tsunezuka, Hiroaki
Kosuga, Toshiyuki
Konishi, Hirotaka
Hongo, Fumiya
Inoue, Masayoshi
Hirano, Shigeru
Ukimura, Osamu
Taguchi, Tetsuya
Takayama, Koichi
Itoh, Yoshito
ONCOLOGY LETTERS, 2020, 20 (04)
[23] Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
Hwang, William L.
Niemierko, Andrzej
Hwang, Katie L.
Hubbeling, Harper
Schapira, Emily
Gainor, Justin F.
Keane, Florence K.
JAMA ONCOLOGY, 2018, 4 (02) : 253 - 255
[24] Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients
Wu, Bing
Sun, Congcong
Sun, Xiaoqin
Li, Xue
MEDICINE, 2022, 101 (36) : E30532
[25] Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients
Kyung-In Joung
Jong Hwa Song
Kangho Suh
Seung-Mi Lee
Ji Hyun Jun
Taehwan Park
Dong Churl Suh
BioDrugs, 2021, 35 : 61 - 73
[26] Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients
Joung, Kyung-In
Song, Jong Hwa
Suh, Kangho
Lee, Seung-Mi
Jun, Ji Hyun
Park, Taehwan
Suh, Dong Churl
BIODRUGS, 2021, 35 (01) : 61 - 73
[27] Comparison of Clinical Outcomes of Patients With Advanced NSCLC In Clinical Trials and in the Real World Received PD-1/PD-L1 Inhibitor
Wang, H.
Wei, C.
Zhang, G. W.
Zhang, M.
Yan, X.
Zhang, X.
Niu, Y. Y.
Yang, J.
Ma, Z.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1017 - S1017
[28] Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
Sadal Refae
Jocelyn Gal
Nathalie Ebran
Josiane Otto
Delphine Borchiellini
Frederic Peyrade
Emmanuel Chamorey
Patrick Brest
Gérard Milano
Esma Saada-Bouzid
Investigational New Drugs, 2020, 38 : 160 - 171
[29] Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
Refae, Sadal
Gal, Jocelyn
Ebran, Nathalie
Otto, Josiane
Borchiellini, Delphine
Peyrade, Frederic
Chamorey, Emmanuel
Brest, Patrick
Milano, Gerard
Saada-Bouzid, Esma
INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 160 - 171
[30] Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Yan, Ting
Yu, Lun
Shangguan, Dangang
Li, Wei
Liu, Ni
Chen, Yun
Fu, Yilan
Tang, Jingyi
Liao, Dehua
INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115

← 1 2 3 4 5 →